Tenofovir Disoproxil Fumarate in the Treatment of Parkinson's Disease
NCT ID: NCT06356662
Last Updated: 2025-02-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1
60 participants
INTERVENTIONAL
2024-01-23
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Efficacy of THN102 in Patients With Parkinson's Disease and Excessive Daytime Sleepiness
NCT03624920
PF-06669571 In Subjects With Idiopathic Parkinson's Disease
NCT02565628
A Study to Evaluate the Efficacy and Safety of HRG2010 in Parkinson's Disease With Motor Fluctuations
NCT06596876
Open Label Sumanirole Study of Safety, Tolerability, and Therapeutic Response In Patients With Parkinson's Disease
NCT00036205
Pharmacokinetics,Pharmacodynamics,Efficacy and Safety of HRG2010 in Parkinson's Disease Patients With Motor Fluctuations
NCT06614153
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Tenofovir
patients with parkinson's disease
Tenofovir Disoproxil Fumarate
take tenofovir disoproxil fumarate 300mg/d
Placebo
patients with parkinson's disease
Tenofovir Disoproxil Fumarate
take tenofovir disoproxil fumarate 300mg/d
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tenofovir Disoproxil Fumarate
take tenofovir disoproxil fumarate 300mg/d
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
2: Or have received deep brain stimulation and other brain surgery
3: Abnormal liver and kidney function
4: Infected with chronic hepatitis B or AIDS (HIV-1 infection)
5: Severe depression, schizophrenia, other psychiatric disorders or drug dependence
6: Other serious physical diseases such as heart, lung, liver, kidney disease, blood disease and malignant tumor
7: Pregnant or lactating women and seniors over 65 years of age
8: Allergy or other contraindications to the investigational drug
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Guohua Zhao
Hangzhou, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KY-2023-198
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.